MedDataX Logo

Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

NCT ID: NCT00140062

Last Updated: 2008-04-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

329 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-02-28

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ocular Hypertension Glaucoma, Open-Angle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

latanoprost 0.005% (Xalatan)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Unilateral or bilateral open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension
* IOP of \> 21 mm Hg on current treatment

Exclusion Criteria

* Any previous or current treatment with latanoprost or other prostaglandin analogues
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Ekenäs, , Finland

Site Status

Pfizer Investigational Site

Helsinki, , Finland

Site Status

Pfizer Investigational Site

Helsinki, , Finland

Site Status

Pfizer Investigational Site

Kuopio, , Finland

Site Status

Pfizer Investigational Site

Lahti, , Finland

Site Status

Pfizer Investigational Site

Rovaniemi, , Finland

Site Status

Pfizer Investigational Site

Seinäjoki, , Finland

Site Status

Pfizer Investigational Site

Tampere, , Finland

Site Status

Pfizer Investigational Site

Turku, , Finland

Site Status

Pfizer Investigational Site

Jönköping, , Sweden

Site Status

Pfizer Investigational Site

Karlstad, , Sweden

Site Status

Pfizer Investigational Site

Kristianstad, , Sweden

Site Status

Pfizer Investigational Site

Linköping, , Sweden

Site Status

Pfizer Investigational Site

Ludvika, , Sweden

Site Status

Pfizer Investigational Site

Mölndal, , Sweden

Site Status

Pfizer Investigational Site

Nacka, , Sweden

Site Status

Pfizer Investigational Site

Norrköping, , Sweden

Site Status

Pfizer Investigational Site

Norrköping, , Sweden

Site Status

Pfizer Investigational Site

Nyköping, , Sweden

Site Status

Pfizer Investigational Site

Örebro, , Sweden

Site Status

Pfizer Investigational Site

Seinajoki, , Sweden

Site Status

Pfizer Investigational Site

Stockholm, , Sweden

Site Status

Pfizer Investigational Site

Stockholm, , Sweden

Site Status

Pfizer Investigational Site

Sundsvall, , Sweden

Site Status

Pfizer Investigational Site

Täby, , Sweden

Site Status

Pfizer Investigational Site

Uppsala, , Sweden

Site Status

Pfizer Investigational Site

Uppsala, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland Sweden

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=912-OPT-0091-156&StudyName=Efficacy+And+Safety+Of+Xalatan+Compared+To+Usual+Care+In+Patients+With+Open+Angle+Glaucoma+Or+Ocular+Hypertension%2E

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

912-OPT-0091-156

Identifier Type: -

Identifier Source: org_study_id